D.E. Shaw & Co
CEROW

D.E. Shaw & Co’s CERo Therapeutics Warrants CEROW Stock Holding History

D.E. Shaw & Co’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,000
Closed -$11K – 6008
2021
Q4 		$11K Buy
+25,000
New +$11.5K ﹤0.01% 5323

Other funds holding CEROW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

D.E. Shaw & Co's CEROW Position: Q1 2022 in Review

D.E. Shaw & Co sold out of CERo Therapeutics Warrants (CEROW) in Q1 2022, closing a stake of 25,000 shares — an estimated $11K sold.

D.E. Shaw & Co first reported a position in CEROW in Q4 2021 and held it in 1 quarter. The position peaked at $11K in Q4 2021. 35 funds tracked by Wall St. Rank hold CEROW as of Q1 2022.

  • D.E. Shaw & Co reported no remaining CERo Therapeutics Warrants position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 25,000 CERo Therapeutics Warrants shares in Q1 2022, an estimated $11K.
  • D.E. Shaw & Co first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's CERo Therapeutics Warrants position peaked at $11K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.